{
    "organizations": [],
    "uuid": "ec4aa80f0fa4b8392839c094c0e093607e988fa4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-promore-pharma-prp-will-finance-de/brief-promore-pharma-prp-will-finance-development-of-pxl01-idUSFWN1SD02E",
    "ord_in_thread": 0,
    "title": "Promore Pharma: PRP Will Finance Development Of PXL01",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 7 (Reuters) - PROMORE PHARMA AB:\n* PROMORE PHARMA OUT-LICENSES PXL01 FOR SPINAL SURGERY TO PHARMARESEARCH PRODUCTS LTD\n* PRP WILL FINANCE DEVELOPMENT OF PXL01 FOR USE TO PREVENT FIBROSIS AFTER SPINAL SURGERY\n* PRP RECEIVED A GLOBAL COMMERCIAL LICENSE OF PXL01 FOR USE IN THIS INDICATION. Source text for Eikon: (Gdynia Newsroom)\nOur ",
    "published": "2018-05-07T14:34:00.000+03:00",
    "crawled": "2018-05-08T16:40:40.041+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "promore",
        "pharma",
        "ab",
        "promore",
        "pharma",
        "pxl01",
        "spinal",
        "surgery",
        "pharmaresearch",
        "product",
        "ltd",
        "prp",
        "finance",
        "development",
        "pxl01",
        "use",
        "prevent",
        "fibrosis",
        "spinal",
        "surgery",
        "prp",
        "received",
        "global",
        "commercial",
        "license",
        "pxl01",
        "use",
        "indication",
        "source",
        "text",
        "eikon",
        "gdynia",
        "newsroom"
    ]
}